Please ensure Javascript is enabled for purposes of website accessibility

Here's What You Need to Know About COVID Variants' Impact on Vaccine Efficacy

By Morgan McSweeney - Updated Mar 31, 2021 at 4:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Do new variants from South Africa, Brazil, and the U.K. threaten the efficacy of already authorized vaccines?

The more widely a virus is circulating in a population and infecting individuals, the more likely it is that the virus will mutate, according to the Centers for Disease Control and Prevention (CDC). Over a year into the global coronavirus pandemic, we face an increasing number of variants of the virus, and the fear that our methods of prevention and treatment might not stack up against the more transmissible and potentially more dangerous strains originating in South Africa, Brazil, and the U.K.

We now have data from Novavax (NVAX 2.04%) and Johnson & Johnson (JNJ -0.09%) on how their vaccines perform against these new strains -- here's what that new data means, and some good news on the ability of shots to provide protection. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$47.07 (2.04%) $0.94
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$179.46 (-0.09%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.